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Drug-dosing recommendations for patients with
acute renal failure (ARF) receiving renal replace-
ment therapy (RRT) have not kept pace with the
advances in RRT technology. Published dosing rec-
ommendations for intermittent hemodialysis (IHD)
typically are based on studies conducted in otherwise
healthy patients with chronic kidney disease (CKD)
treated with older low-permeability hemodialyzer
membranes thrice weekly. Drugs, such as vanco-
mycin, that were not appreciably removed by these
conventional dialysis membranes, are removed by
newer high-permeability dialyzer membranes (1,2).
Nonetheless, recently published dosing guidelines 
do not reflect these changes in vancomycin dialytic
removal (3,4). CRRT dosing guidelines are finally
becoming available (4,5), but the dosing guidelines
are based on low ultrafiltrate and dialysate flows with
older hemodiafilters, often conducted in the arterio-
venous mode. The growth of higher delivered RRT
doses in critically ill patients with ARF has rendered
these dosing guidelines ineffectual and, potentially,
dangerous.
Discussions about the merits and faults of higher
delivered RRT doses often include discussions of
sepsis and mediator removal (6,7), but not of antibi-
otic removal to treat the causative infection. Indeed,
drug dosing in high-dose renal replacement ther-
apy (HRRT) was excluded from discussion in the
first consensus conference on CRRT (8). Patient out-
comes with higher delivered therapy has resulted in
mixed results (9–11), but consideration of the effect
that these therapies have on the removal of life-
saving drugs is understated. Costs of increased RRT
have begun to be quantified (12,13), but costs related
to pharmacotherapy (drug cost, administration costs,
additional lab costs, etc.) have not been included in
these analyses. The purpose of this article is to discuss
pharmacokinetic and pharmacodynamic issues of
higher delivered RRT doses and to stimulate aware-
ness of this aspect of treating the critically ill patient
requiring of higher delivered doses of RRT.
Most clinicians are familiar with a drug’s pharma-
cokinetics, or how the body handles a drug once it is
administered. Fewer are familiar with the concept of
pharmacodynamics. Pharmacodynamics is the study
of the biochemical and physiological effects of drugs
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profound effects on pharmacotherapy, yet little research
has been conducted in this area. High-volume renal re-
placement therapies influence both the pharmacokinetic
and the pharmacodynamic profiles of all drugs adminis-
tered to these critically ill patients. Intermittent high-dose
“hybrid” hemodialysis therapies remove drugs to a much
different degree than standard thrice-weekly hemodialysis,
yet pharmacokinetic studies have not been performed in
patients receiving these therapies. High-volume continu-
ous renal replacement therapies offer dosing challenges
not seen with standard low-dose therapies. This article
describes the pharmacokinetic and pharmacodynamic
issues presented by high-volume renal replacement thera-
pies. Given the importance that pharmacotherapy has on
optimal patient outcomes, a better understanding of the
influence that high-volume renal replacement therapy has
on drugs is essential if these high volume therapies are 
to be used successfully in the intensive care unit. Key
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and their mechanisms of action, or, in other words,
how the drug affects the body. Clinically, we are 
more interested in the pharmacodynamics of a drug,
because it is these drug effects that determine a cure
or amelioration of symptoms. RRT can influence
both pharmacokinetics and pharmacodynamics.
Pharmacokinetics
The influence of older, lower volume CRRT re-
gimens and thrice-weekly IHD regimens on drug 
and solute removal are fairly well understood. The
low-flow CRRT regimens can be thought of as an
artificially functioning kidney providing continual
first-order drug clearance. Solute dialytic clearance
data from patients with CKD were extrapolated 
to thrice-weekly IHD regimens in critically ill ARF
patients. However, these generalized approaches 
are not entirely correct. For example, dialytic drug
clearance during hemodialysis in ARF patients 
likely differs from that of an otherwise healthy 
CKD patient. In the unstable ARF patient, blood
flow (Qb) often cannot be maintained at rates that
can be maintained in the CKD patient. Other phar-
macokinetic differences exist between patients with
ARF and CKD. Unlike stable CKD patients, ARF
patients often are massively fluid overloaded, which
may result in a larger volume of distribution for
water-soluble drugs with relatively small apparent
volumes of distribution (e.g., aminoglycosides).
CRRTs are able to effectively remove this fluid,
which yields a patient with a rapidly changing 
apparent drug volume of distribution. A smaller 
apparent volume of distribution yields a higher 
relative Kt/Vurea at the same dialysate rate (Qd) or
ultrafiltration rate (Quf), and consequently it yields
a higher Kt/Vdrug as well. Continuous therapies do not
always yield stable drug removal, as Qb and Quf are
quite variable in CAVH therapies, for example.
Figure 1 illustrates a pharmacokinetic model that
demonstrates many important pharmacokinetic chal-
lenges of HRRT. Nephrologists dose dialysis based
on urea clearance, and in the course of monitoring
BUN, have noted that urea exhibits characteristics
suggestive of a two-pool or two-compartment model.
The best evidence of this is the fact that urea serum
concentrations rebound soon after hemodialysis
ends. Most drugs will exhibit a similar “rebound”
(2,14,15), and pharmacokinetic experiments have
found that many drugs exhibit two and three com-
partment characteristics. One often refers to the first
(central) compartment as the plasma space, whereas
the other compartments are “deeper” compartments
representative of various tissues in the body. In 
truth, it is difficult to state exactly which anatomical
space(s) corresponds to each modeled compartment.
Much of drug distribution depends on factors such 
as the drug’s lipophilicity, and the degree of protein
and tissue binding. The rate of transfer between 
these compartments is typically determined mathe-
matically as opposed to simultaneously sampling
plasma and other anatomical spaces in order to
determine drug concentration. Much of this concern
over pharmacokinetic modeling would be an acade-
mic pharmacokinetic discussion were it not for the
advent of HRRT.
In standard low-dose CRRT, the rate-limiting step
of solute clearance (including drugs) has been Qd
and/or Quf because Qb greatly exceeds Qd or Quf.
The rate of drug removal by low-dose CRRT from
the first compartment is probably slower than the
rate of transfer of the drug from the deep com-
partment(s) to the first compartment (K21, K31).
Consequently, no appreciable rebound occurs after
low-dose CRRT stops because drugs transfer to the
first compartment at least as fast as the drug is being
removed by the CRRT. With high-volume CRRT, a
process more like what is seen in IHD occurs. With
HRRT, the drug is rapidly removed from the first
(plasma) compartment if the drug has the appropri-
ate characteristics. At HRRT initiation, the first com-
partment becomes rapidly stripped of unbound drug.
The rate-limiting step of any further drug removal
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FIG. 1. Depiction of a pharmacokinetic view of drug removal by
RRT. The patient is to the right of the vertical dotted line and the
RRT is on the left. Most solutes exhibit multicompartment char-
acteristics in patients, consisting of central and peripheral com-
partments. Solutes are removed from the central compartment
either by RRT or through nonextracorporeal means. In HRRT,
drugs are rapidly cleared from the first compartment, possibly
even faster than the drugs can equilibrate from other deeper
compartments. In this scenario, the rate-limiting step for drug
removal becomes how fast the drug can transfer to the central
compartment from these deeper compartments.
becomes the rate at which drug can transfer from the
deeper compartments into the first compartment for
removal by HRRT. Similarly, the size of the com-
partments (apparent volumes of distribution) of each
drug also influences actual drug removal. Just like
identification of where anatomically the deeper 
compartments exist is difficult without being able 
to sample from these spaces, actual transfer rates
between compartments are very difficult to rigor-
ously determine. Further complicating this picture is
the likelihood that every drug has a different set of
transfer rates and distribution volumes and that these
differ for each patient (just like any other pharma-
cokinetic parameter). However, clinicians should
recognize that HRRT drug removal might change
from when HRRT is initiated to later in therapy
when the first (plasma) compartment has been
stripped of drug. Serum concentration monitoring
and thoughtful interpretation of those results in
HRRT are essential.
Drug and urea clearances via low-volume contin-
uous hemodialysis (CVVHD) and hemofiltration
(CVVH) have been considered to be equivalent.
Large molecular weight substances may have been
more readily cleared with convection than diffusion,
but these differences are thought to be negligible.
Indeed, at low flows, drug-dosing recommenda-
tions for low-volume CRRT have not differentiated
between the diffusive and convective clearance. In 
a purely convective therapy, such as CVVH, the 
appropriate measure of a solute’s ability to cross 
the membrane is the sieving coefficient (SC). SC is
calculated as the ratio of ultrafiltrate solute concen-
tration divided by the simultaneous arterial solute
concentration. SC is generally thought to be un-
changed despite changes in Quf, although this has 
not been thoroughly investigated. In contrast, the cal-
culation of dialytic clearance requires the use of the
saturation coefficient (SA). At a fixed set of blood
and dialysate flow rates, the SA equals the ratio of
spent dialysate solute concentration divided by the
simultaneous arterial solute concentration. Early
low-volume-based CRRT dosing guidelines sug-
gested that SA = SC (16,17). This assumption is
appropriate with low-volume CRRT because Qd is
slow enough to allow almost complete equilibrium 
of solute concentration between the dialysate and
blood sides of the dialysis membrane. However, this
assumption is almost certainly incorrect with high-
dose CRRT.
Few studies have been conducted on the issue of
SA and SC differences in high-dose CRRT, but early
reports suggest a marked difference between the two.
The difference likely will be more pronounced with
larger molecular weight substances than smaller 
substances because diffusivity is inversely related to 
molecular size. As molecular size increases, the dif-
ference between SA and SC should grow, although
this difference will likely be dependent on hemo-
filter characteristics. Clinically, this separation of 
SA and SC ought to be seen with solutes of larger
molecular weight.
The SA of urea and vancomycin (molecular weight
65 and ~1,450 Daltons, respectively) were deter-
mined in an in vivo trial conducted in CKD patients
receiving experimental CVVHD at varying dialysate
flow rates (5). At relatively low Qd (8.3 ml/min), the
SA for urea and vancomycin were between 0.71 and
0.88, and 0.63 and 0.9, respectively. The variation of
SA was found to be hemodiafilter dependent.
However, as Qd increased from 8.3 ml/min up to 
33.3 ml/min, the SA of each solute changed from a
9% increase to a 30% decline. The largest decline
(30% decline in vancomycin SA and 8% decline in
urea SA) was seen with AN69 hemodiafilters, a com-
monly used hemofilter in HRRT. Using this same
AN69 hemodiafilter (Multiflow 60, Hospal, Lyon,
France), Brunet found that increasing dialysate 
flow rates above 1,000 ml/hr did not enhance b-2
microglobulin clearance (molecular weight 11,600
Daltons) (18). In contrast, smaller drugs such as cef-
tazidime tend to have increased dialytic clearance as
dialysate flow is increased (19). These data indicate
that doubling dialysate flow rates from standard low-
volume flows (1,000 ml/hr) to higher dialysate flows
(2,000 ml/hr) may result in substantially less than a
doubling of solute dialytic clearance, particularly 
for larger solutes. Increasing dialysate flow rates
(≥2,000 ml/hr) should result in decreasing SA, but the
rate of SA decline is filter dependent (5).
Many centers utilizing HRRT use a combination
of diffusion and convection, hemodiafiltration. These
combination therapies provide the most difficulty in
determining rational drug dosing because all of the
concerns of purely diffusive (differences between SA
for solutes of differing molecular weight at higher
flows, assumption that SA = SC, etc.) and convective
therapies (predilution of replacement solutions
affecting convective solute clearance, hemoconcen-
tration throughout the length of the filter resulting in
premature clotting, inability to achieve desired UF
rate at high-UF flow rates, etc.) become critical issues
in high-volume hemodiafiltration. The combination
of diffusive and convective therapies results in addi-
tional solute removal confounders. Brunet deter-
mined the small solute (urea, creatinine, urates, and
phosphorus) and b-2 microglobulin clearances in
purely dialytic and purely convective RRT operated
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at varying rates (18). These clearances were added
together and compared to clearances achieved by a
hemodiafiltrative therapy using the same dialysate
and ultrafiltration rates given simultaneously. When
convection and diffusion occurred simultaneously, as
in hemodiafiltration, the clearance of large solutes
such as b-2 microglobulin was less than what was
attained by adding the expected clearances of the
convective and diffusive if they were delivered inde-
pendently (18). The mathematics behind the inter-
action of convection and diffusion are complex 
(20). However, it is likely that the hemodiafiltrative 
clearance of large drugs such as vancomycin, dapto-
mycin, teicoplanin, and the aminoglycosides will
differ from that attained by purely convective or 
diffusive therapies. Concurrent diffusion and con-
vection will result in lower drug clearances than what
is achievable by these therapies given individually,
but so few data exist on this issue that determining
appropriate drug-dosing regimens in patients receiv-
ing high-volume continuous hemodiafiltration is
exceedingly difficult.
Pharmacodynamics
Our understanding of antibiotic therapy has
matured over the past years as pharmacodynamic
research has influenced how we dose drugs in
infected patients. For example, the expanded use of
dosing regimens like “once-daily aminoglycosides”
in patients with normal renal function have come
into being because data suggest that aminoglyco-
sides have a long postantibiotic effect against many
Gram’s stain-negative bacteria. In most hospitals, this
method of aminoglycoside dosing has replaced con-
ventional dosing (lower doses given more often) due
to equal or better cure rates with lower toxicity rates
(21). Other antibiotics have different bactericidal
and bacteriostatic pharmacodynamic characteris-
tics that have recently come to light. Consequently,
dosing regimens, based on these pharmacodynamic
characteristics, have been developed to capitalize on
a drug’s pharmacodynamic properties. By virtue of
their ability to affect drug pharmacokinetics, HRRT
is also likely to influence pharmacodynamics. Thus,
conventional drug-dosing schemes may need adjust-
ment due to the pharmacokinetic and pharmaco-
dynamic influences of HRRT.
There are many examples of where HRRT may
have profound clinical effects on antibiotic pharma-
codynamics. The pharmacodynamics of aminoglyco-
sides are well described. Aminoglycosides work 
most effectively when high maximal serum concen-
tration (Cmax) in relation to the organism’s minimal
inhibitory concentration (MIC) is achieved. Once-
daily dosing can be used due to the prolonged post-
antibiotic effect, and microbiologic cure without high
toxicity can be attained provided the high Cmax/MIC
ratio is reached (22,23). Once-daily aminoglycoside
regimens are contraindicated in patients with kidney
disease. Consequently, conventional dosing is most
often used in patients with acute renal failure. It is
possible the enhanced drug clearance of HRRT may
allow for the use of once-daily aminoglycoside dosing
in these critically ill infected patients.
In contrast to aminoglycosides, other antibiotics
require a different pharmacodynamic profile to be
maximally effective. Beta lactam antibiotics require
the maintenance of serum concentrations above the
MIC of the infecting organism at the infection site. In
the case of beta lactams, it is likely that those that are
not highly protein bound are rapidly removed by
HRRT and that much more frequent dosing is re-
quired to meet this pharmacodynamic requirement.
Indeed, some have suggested continuous beta lactam
antibiotic infusions to treat infections in patients
without acute renal failure (24). It is possible that
continuous beta lactam infusions might also be effec-
tive in infected ARF patients treated with HRRT.
Like beta lactams, vancomycin is most effective
when serum concentrations remain above critical
MIC values. Positive patient outcomes with van-
comycin have been associated with the maintenance
of trough serum concentrations above 10 mg/L (25).
HRRT, particularly convective therapies using high-
flux membranes, should efficiently clear vancomycin
(5,26). Consequently, more frequent dosing and
serum concentration monitoring will be essential 
to maximize therapeutic outcomes and minimize 
toxicity.
Similar to aminoglycosides, the pharmacodynamic
profile of fluoroquinolones is known to require 
prolonged serum concentrations (as measured by 
the area under the serum concentration time curve
for 24 hr, AUC0–24) above the MIC. Maintenance of
the AUC0–24/MIC and Cmax/MIC ratios above critical
values has been shown to correlate with clinical 
and bacteriologic outcomes for this antibiotic class
(23,27).
In addition, a suboptimal AUC0–24/MIC ratio has
been shown to be strongly associated with the selec-
tion of antimicrobial resistance during therapy (28).
As HRRT will affect fluoroquinolone pharmaco-
kinetics, consequently fluoroquinolone pharmaco-
dynamics will be compromised as well. As HRRT
removes higher amounts of the fluoroquinolone, the
serum concentrations fall, resulting in lower ratios.
Antibiotic dosing recommendations that are mind-
ful of the pharmacokinetic and pharmacodynamic
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influences of HRRT must be developed for HRRT
to become a fully mature therapy.
Pharmacodynamic influences of HRRT go beyond
simply affecting antibiotic pharmacokinetics. For
example, HRRT is often suggested as a treatment
option for septic shock. Clearly sepsis mediators are
removed by HRRT (6,7,29,30), and removal of these
mediators may provide a salutary effect, but thus far
the evidence for this benefit in humans is scant (6–8).
In addition to the removal of the “bad” mediators by
HRRT, it is possible that beneficial cytokines are
removed as well (31). These cytokines may augment
the action of antibiotics, and their removal by HRRT
may influence the pharmacodynamics of adminis-
tered antibiotics. The clinical aspects of this antibiotic
and beneficial cytokine removal have yet to be 
determined.
Previously published dosing guidelines
Many recommendations for determining the
appropriate drug dosing for RRT have been pub-
lished. Intermittent dialysis dosing recommendations
appear in most drug package inserts and in textbooks
(4). However, the hemodiafilters, flows, and treatment
times from which these recommendations are based
are considerably different than what are used in
HRRT. Recommendations based on standard IHD
have almost no applicability to HRRT involving dial-
ysis. Very few studies have been published for the
high-volume hybrid dialysis therapies such as SLED,
but they do indicate large differences in drug removal
between low-volume and hybrid HRRT (32).
Dosing guidelines for continuous therapies typi-
cally are not presented in a drug’s package insert.
Perhaps it is time for this to be required for those
drugs commonly used in patients with ARF. Pub-
lished CRRT dosing texts typically are based on low-
volume therapies (3,4). Recommended doses likely
would require large changes to be used in patients
receiving HRRT.
Actual pharmacokinetic studies conducted in
patients receiving HRRT are rare, though a few have
been published recently. Most of these reports focus
on antibiotics that are used in critically ill patients
with acute renal failure (33–36). These are typically
case reports or small case series. Care must be made
when attempting to extrapolate the author’s rec-
ommendations to patient care, as there are great 
differences between filter types and flow rates.
Pharmacodynamic goals of drug therapy must be
considered before determining a dosing regimen, and
they are not always assessed in these reports.
Nonetheless, many dosing algorithms have been
developed for continuous therapies that can be mod-
ified for the individual flow rates used in continuous
HRRT. These approaches can be grouped into 
two types. Method 1 begins with the drug’s dos-
ing regimen in normal renal function and adjusts 
it downward to the ultrafiltrate/dialysate flow rates
(20,37). Method 2 begins with the dosing regimen
used in chronic kidney disease and applies a dosing
multiplication factor to account for extracorporeal
clearance (16,17,38,39). Table 1 provides some com-
parisons of the calculated daily maintenance drug
requirements using these two methods with CRRT at
varying dialysate/ultrafiltration rates.
A review of Table 1 reveals that these published
dosing methods do not perform well with HRRT.
Indeed, in many cases, clinical judgment precludes
the use of some of these recommendations (shaded
areas of Table 1) even at the lower dialysate/ultrafil-
tration rates. Indeed, it is interesting how much of a
difference in calculated gentamicin and vancomycin
doses there is even at dialysate/ultrafiltrate rates 
of 1,000 ml/hr. Clinical experience indicates that
method 1 appears to perform better than method 2,
particularly for drugs with higher sieving coefficients.
Due to the equations used, method 2 consistently
overestimates the daily dosing needs for drugs with
low nonrenal clearance rates in anuria. For drugs
with lower sieving coefficients, method 1 tends to
result in higher doses than method 2. These two
dosing methods produce similar results at all flow
rates for only two of the five drugs (ciprofloxacin and
phenobarbital) in Table 1.
Both dosing methods have inherent flaws, and 
the authors of methods 1 and 2 acknowledge the 
limitations of these proposed dosing algorithms
(16,17,38,39). Whether one starts with the doses for
patients with normal renal function or patients with
CKD, it is evident that there are fundamental phar-
macokinetic differences between these patients and
critically ill patients with ARF treated with HRRT.
Differences between normals and patients with CKD
or ARF with respect to volume status, drug pro-
tein binding, and nonrenal drug clearance are well
described. Pharmacokinetic studies conducted with
imipenem (33,40) and vancomycin (41) have shown
that application of pharmacokinetic drug properties
such as nonrenal drug clearance derived in patients
with CKD would result in serious dosing errors.
With both of these drugs, the nonrenal clearance in
ARF is substantially higher than that seen in CKD
patients. Doses assuming the nonrenal clearance of
CKD will result in severe underdosing of these
antibiotics.
Both dosing methods assume that SA and SC
remain constant at any combination of ultrafiltrate
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and dialysate flow rates. This assumption is most cer-
tainly incorrect, but in the absence of SA/SC data at
high flows and combinations of flows, it may be the
best available guess. Finally, all of these approaches
are based on inferences made from adult patients.
High-volume therapies are being used increasingly in
children. Drug-dosing challenges in pediatric patients
receiving HRRT are vast, and it is unlikely that the
solution to them will be found in these algorithms.
Higher drug doses tend to be used in HRRT, and
simple changes in patient management can lead to
disastrous results. When HRRT systems are stopped
due to filter clotting, access problems, patient trans-
portation, or procedures, drug-dosing regimens must
be altered immediately to prevent acute overdoses
and toxicity. Conversely, HRRT initiation requires
rapid changes in drug dosing to compensate for the
extracorporeal drug clearance. Titration of vasopres-
sor, paralytics, anticoagulants, and pain medications
may be necessary as HRRT parameters change.
Conclusion
The growth of HRRT in ICUs around the world
presents great challenges to the delivery of appro-
priate pharmacotherapy. Pharmacotherapy in HRRT
is a rich area for research, as currently published
guidelines were not designed for these RRT and do
not work well when they are used in HRRT. These
high-volume therapies may prove to be superior to
low-volume therapies in selected patients, but they
will not be found to be so until we have a better
understanding of pharmacotherapy management in
HRRT.
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